close and back to page

Latest News

Latest News

A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott

Abbott has been named a top employer by Science, evaluated by 6,950 people in science fields around the world.

Science has spoken: Abbott (No. 10 on the DiversityInc Top 50 Companies list) is, again, among the best science-based companies to work for in the world.


For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.

At Abbott, scientists develop life-changing technologies that help people live their best lives through good health. From freeing people with diabetes from routine finger sticks1, to building a cardiac device to save lives, to hunting for new virus mutations, every day Abbott employees are doing work that matters.

"Abbott's diverse businesses and product lines open up exciting career opportunities for our scientists across a range of technologies," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track.

"We strive to foster a culture of innovation and collaboration within our teams and in our work with others to gain fresh perspectives and further inspire our scientists to continue to push the boundaries on scientific advancements. This contributes to a strong, vibrant and fulfilling environment for scientists to develop their careers – and supports Abbott's long, successful legacy of scientific achievement and game-changing technology."

Our spirit of innovation and relentless focus on pushing the frontiers of science have allowed our company to thrive for more than 125 years. Today, we're working tirelessly to carry on that great legacy and to address some of healthcare's greatest challenges.

Some of Abbott's latest breakthroughs include:

  • A unified family of innovative next-generation diagnostics systems across lab disciplines that offer more efficiency, flexibility and confidence to health systems, and better help doctors and nurses get the results they need to improve decision-making and patient care.
  • Our revolutionary diabetes technology that replaces blood glucose monitoring, freeing people with diabetes from the pain and hassles of routine fingersticks.
  • Pioneering neuromodulation technology that can transform quality of life for many people who are otherwise unable to find relief from their chronic pain, while also reducing or stabilizing opioid use among patients battling chronic pain conditions.
  • first-of-its-kind cardiac device that has transformed the treatment of certain kinds of mitral regurgitation (MR) for people who are too frail for open-heart surgery or those who are not candidates for surgery.
  • Groundbreaking research that has helped bring infant formula closer than ever to breast milk.

Learn more about career opportunities at Abbott

ABOUT THE 2017 SCIENCE SURVEY

The 2017 Science survey sought to identify the companies with the best reputations as employers. The findings are based on 6,950 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (65%), Europe (25%) and Asia/Pacific Rim (7%); 94% work in biotechnology, biopharmaceutical and pharmaceutical companies. Here's a complete list of the rankings, which also are available in the Oct. 20, 2017 print edition of Science.

1 A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the system or when symptoms do not match the system readings.

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less

Abbott: Expediting Blood Testing With i-Stat

The portable, handheld i-STAT Alinity delivers quick blood test results anywhere you are.

Originally Published by Abbott.

Every day, countless blood samples are tested all around the world for one purpose: to help diagnose and treat medical conditions. From the couple eagerly awaiting the results of a pregnancy blood test to a worried cancer patient hoping for more answers, diagnostic blood tests give vital insight into what's happening underneath the skin.

Read More Show Less

Abbott: Freestyle Libre 14 Day, Now FDA Approved

Abbott's flash glucose monitor now FDA-approved for two weeks of use in U.S. between sensor changes.

Originally Published by Abbott.

The U.S. Food and Drug Administration has approved FreeStyle Libre 14 day— Abbott's revolutionary continuous glucose monitoring system. In the U.S., you can wear the sensor up to 14 days with high accuracy.

Read More Show Less

At Abbott, You Look Like An Engineer

Decades before #ILookLikeAnEngineer, Abbott paved the way for a non-profit dedicated to diversity in STEM.

Originally Published by Abbott.

#ILookLikeAnEngineer.

Remember this? A few years ago, a young software engineer was featured in a recruiting advertisement, only to be accused of not being an actual engineer. Frustrated with the assertion, Isis Wenger started a movement to break the stereotype of what an engineer should look like.

Read More Show Less

Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves

MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair.

Originally Published by Abbott.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

Read More Show Less